Method for treatment of osteoporosis
AssigneeBiodyn Medical Research, Inc.
InventorStephen Sawruk
Life of this patent
Estimating the term…
Abstract
A method for orally inducing and enhancing the absorption of calcium into mammalian bone tissue comprises the administration of an effective dose of a flavonol aglycone glycoside in combination with nutritional calcium. Various herbal sources are shown. Potassium gluconate may be added to the system as an adjuvant.
Claims19
A method for orally inducing and enhancing calcium absorption into mammalian bone tissue in a patient in need of such treatment comprising the periodic administration of a composition consisting essentially of:
- (a) a flavonol aglycone glycoside in an amount effective to induce and enhance the absorption of calcium into mammalian bone tissue;
- (b) an effective dose of nutritional calcium;
- and
- (c) pharmaceutically acceptable and pharmacologically inactive excipients.
A method for orally inducing and enhancing calcium absorption into mammalian bone tissue in a patient in need of such treatment comprising the periodic administration of a composition consisting essentially of:
- (a) a flavonol aglycone glycoside administered in a daily dose of about 50 to about 250 mg;
- (b) nutritional calcium administered in a daily dose of about 500 to about 1500 mg;
- (c) pharmaceutically acceptable and pharmacologically inactive excipients;
- and
- (d) potassium gluconate administered in a daily dose of about 50 to about 250 mg.
A pharmaceutical composition for the treatment of osteoporosis in mammalian bone tissue consisting essentially of:
- (a) a flavonol aglycone glycoside in an amount effective to induce and enhance the absorption of calcium into mammalian bone tissue;
- (b) an effective dose of nutritional calcium;
- and
- (c) pharmaceutically acceptable and pharmacologically inactive excipients.
A pharmaceutical composition for the treatment of osteoporosis in mammalian bone tissue consisting essentially of:
- (a) a flavonol aglycone glycoside present in the amount of 50-250 mg/daily dose;
- (b) nutritional calcium present in the amount of 500-1500 mg/daily dose;
- (c) pharmaceutically acceptable and pharmacologically inactive excipients;
- and
- (d) potassium gluconate in an amount of about 50 to about 250 mg/daily dose.
Dependencies are inferred from the claim text.